Niksa Kastrapeli | Associate Director
Shire

Appearances:

Day 1 Antibody Congress @ 09:30

PLENARY KEYNOTE: Discovery, characterization and proof of concept study for an antibody inhibitor of Factor XIIa

Plenary

•     Preclinical data for development of DX-4012 as an inhibitor of Factor XIIa
•     This shows potential as a novel antithrombotic therapy
•     Future interest areas and implications for autoimmune disorders and thrombosis

Niksa Kastrapeli, Associate Director, Shire